Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation

Phase 2 Completed 7 enrolled Ionis Pharmaceuticals, Inc.

RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to evaluate whether treatment with ISIS CRP Rx can reduce AF (Atrial Fibrillation) burden (percentage of time spent in AF) in subjects with paroxysmal AF

Timeline

Start: 2012-10
Primary completion: 2014-04
Completion: 2014-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ISIS CRP Rx	Antisense oligonucleotide	—	—

Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation

Summary

Timeline

Drugs

Indications